Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varenicline for nicotine vaping cessation in adolescents (Pilot)
NCT04602494Phase 4Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2020
- Primary completion
- Jun 2022
- Countries
- 1
01
Overview
Phase 4, randomised, triple-blind trial of varenicline in nicotine dependence (3 arms), sponsored by Massachusetts General Hospital. Primary endpoints: Percentage of Participants With Continuous Nicotine Vaping Abstinence From Week 9 Through End of Treatment (Week 12), Percentage of Participants With Continuous Nicotine Vaping Abstinence From Week 9 Through End of Follow-up (Week 24) and 6 more. Started Dec 2020; status: terminated.
02
Drugs
varenicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT04602494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04602494.